HRMY Harmony Biosciences Holdings
Company Analysis
Latest News
🟢 Harmony Biosciences is trading 4.01% up today after setting Q2 2026 earnings date
Harmony Biosciences is trading 4.01% up at $34.84 after the company announced it will report second quarter 2026 financial results on August 4, 2026. * The...
Harmony Biosciences preannounces record second quarter 2026 revenue of $261 million, reaffirming full-year guidance.
Harmony Biosciences preannounced preliminary second quarter 2026 net product revenue of approximately $261 million, a 30% increase year-over-year. The company...
🔴 Harmony Biosciences is trading 4.1% down today as investors weigh Wakix patent litigation risks
Harmony Biosciences is trading at $36.63 (4.1% down) amid ongoing volatility tied to Wakix patent litigation and shifting analyst views on long-term...
Harmony Biosciences Reaffirmed at Mizuho, Trial Review Supports Wakix Patent
Mizuho reiterated its Outperform rating and $50.00 price target for Harmony Biosciences. The firm issued the update after reviewing trial transcripts regarding...
🟢 HRMY is trading 4.5% up today as it tests resistance amid healthcare sector rotation
HRMY is trading at $38.66 (up 4.5%) as the stock maintains strong bullish momentum and technical strength. • The stock is currently testing a key resistance...